SCHEMBL15518133

SCHEMBL15518133

Cc1cncc2sc(C(N)=O)cc12

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ICAM1 P05362 15/20 0.67
▸ SELE P16581 15/20 0.67
▸ VCAM1 P19320 5/20 0.67
▸ CDK8 P49336 3/20 0.59
▸ CCNC P24863 2/20 0.59
▸ MEN1 O00255 1/20 0.59
▸ KMT2A Q03164 1/20 0.59
▸ PIM1 P11309 5/20 0.58
▸ GSK3A P49840 5/20 0.58
▸ CDK5 Q00535 5/20 0.58
▸ KDR P35968 4/20 0.58
▸ RPS6KA3 P51812 4/20 0.58
▸ LIMK1 P53667 4/20 0.58
▸ GSK3B P49841 4/20 0.58
▸ CDK1 P06493 4/20 0.58
▸ CDK2 P24941 4/20 0.58
▸ DYRK1A Q13627 4/20 0.58
▸ DAPK3 O43293 3/20 0.58
▸ PRKACA P17612 3/20 0.58
▸ MAPK8 P45983 3/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19769120 0.85 ICAM1 (0.58) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL24721595 0.85 PLK4 (0.59) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL29069393 0.81 ICAM1 (0.69) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL30568694 0.80 ICAM1 (0.67) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL14023789 0.80 ICAM1 (0.67) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL742713 0.80 ICAM1 (0.67) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL7054697 0.80 ICAM1 (1.00) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL8115621 0.80 ICAM1 (0.61) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL7056141 0.79 ICAM1 (0.65) ICAM1SELEVCAM1CDK8CCNC
SCHEMBL7057206 0.77 ICAM1 (0.64) ICAM1SELEVCAM1CDK8CCNC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION NAKAMURA, ROBERT 2018-01-18 — — US disclosed
WO-2014035829-A1 SUBSTITUTED 3-AMINOTHIENO[2,3-C]PYRIDINE-2-CARBOXAMIDE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS VANDERBILT UNIVERSITY (US) 2014-03-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180015077-A1 COMPOUNDS AND METHODS FOR TREATING HIV INFECTION CD4, CCR5, MMP8 ICAM1 65/4885SELE 751/4885VCAM1 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback